Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies

Brain

Volumn 140, Issue 3, 2017, Pages 764-780

  Ono, Maiko ^a,i   Sahara, Naruhiko ⁱ   Kumata, Katsushi ⁱ   Ji, Bin ⁱ   Ni, Ruiqing ^b   Koga, Shunsuke ^c   Dickson, Dennis W ^c   Trojanowski, John Q ^d   Lee, Virginia M Y ^d   Yoshida, Mari ^e   Hozumi, Isao ^f   Yoshiyama, Yasumasa ^g   Van Swieten, John C ^h   Nordberg, Agneta ^b   Suhara, Tetsuya ⁱ   Zhang, Ming Rong ⁱ   Higuchi, Makoto ⁱ  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MAYO GRADUATE SCHOOL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e AICHI MEDICAL UNIVERSITY   (Japan)

^f GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^g SAKURA NATIONAL HOSPITAL   (Japan)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Alzheimer s disease; N279K G272V FTDP 17 MAPT mutation; PBB3 AV 1451; Progressive supranuclear palsy corticobasal degeneration Pick s disease; Tau PET ligand

Indexed keywords

2 [4 [6 (METHYLAMINO)PYRIDINE 3 YL]BUTA 1,3 DIENYL]BENZO[D]THIAZOL 6 OL]; 2 [[4 [6 (METHYLAMINO)PYRIDINE 3 YL]BUTA 1,3 DIENYL]BENZO[D]THIAZOL 6 OL] C 11; FLORTAUCIPIR; FLORTAUCIPIR F 18; PBB 3; RADIOLIGAND; TAU PROTEIN; UNCLASSIFIED DRUG; 1,3 BUTADIENE DERIVATIVE; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; BENZO-1,2,3-THIADIAZOLE; BENZOTHIAZOLE DERIVATIVE; CARBOLINE DERIVATIVE; PBB3 COMPOUND; PHENAZOPYRIDINE; RADIOPHARMACEUTICAL AGENT; THIADIAZOLE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; BRAIN HOMOGENATE; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DIFFUSE NEUROFIBRILLARY TANGLES WITH CALCIFICATION; DRUG SELECTIVITY; FAMILIAL DISEASE; FIBRIL; FLUORESCENCE ANALYSIS; FLUORESCENCE MICROSCOPY; GENE MUTATION; GLIA CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIGAND BINDING; NERVE CELL; NERVE DEGENERATION; NEURITE; PICK PRESENILE DEMENTIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; TAUOPATHY; BRAIN; CHEMISTRY; DIAGNOSIS; DIAGNOSTIC IMAGING; DRUG EFFECTS; FEMALE; FLUORESCENCE; MALE; METABOLISM; NEUROFIBRILLARY TANGLE; PATHOLOGY; RADIOASSAY;

AUTORADIOGRAPHY; BENZOTHIAZOLES; BRAIN; BUTADIENES; CARBOLINES; DIAGNOSIS; FEMALE; FLUORESCENCE; HUMANS; MALE; NEUROFIBRILLARY TANGLES; PHENAZOPYRIDINE; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; TAU PROTEINS; TAUOPATHIES; THIADIAZOLES;

EID: 85013493140     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww339     Document Type: Article

References (49)

1. Arvanitakis Z, Witte RJ, Dickson DW, Tsuboi Y, Uitti RJ, Slowinski J, et al. Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism Relat Disord 2007; 13: 230–9.
2. Berriman J, Serpell LC, Oberg KA, Fink AL, Goedert M, Crowther RA. Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci USA 2003; 100: 9034–8.
3. Bibow S, Mukrasch MD, Chinnathambi S, Biernat J, Griesinger C, Mandelkow E, et al. The dynamic structure of filamentous tau. Angew Chem Int Ed Engl 2011; 50: 11520–4.
4. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239–59.
5. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013; 34:457–68.
6. Daebel V, Chinnathambi S, Biernat J, Schwalbe M, Habenstein B, Loguet A, et al. b-Sheet core of tau paired helical filaments revealed by solid-state NMR. J Am Chem Soc 2012; 134: 13982–9.
7. Delisle MB, Murrell JR, Richardson R, Trofatter JA, Rascol O, Soulages X, et al. A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy. Acta Neuropathol 1999; 98: 62–77.
8. de Silva R, Lashley T, Strand C, Shiarli AM, Shi J, Tian J, et al. An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathol 2006; 111: 329–40.
9. Dickson DW, Ksiezak-Reding H, Liu WK, Davies P, Crowe A, Yen SH. Immunocytochemistry of neurofibrillary tangles with antibodies to subregions of tau protein: identification of hidden and cleaved tau epitopes and a new phosphorylation site. Acta Neuropathol 1992; 84: 596–605.
10. Feany MB, Dickson DW. Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 1995; 146: 1388–96.
11. Flament S, Delacourte A, Verny M, Hauw JJ, Javoy-Agid F. Abnormal Tau proteins in progressive supranuclear palsy. Similarties and differences with the neurofibrillary degeneration of the Alzheimer type. Acta Neuropathol 1991; 81: 591–6.
12. Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brains isoforms. Neuron 1992; 8: 159–68.
13. Goedert M, Falcon B, Clavaguera F, Tolnay M. Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr Neurol Neurosci Rep 2014; 14: 495.
14. 18F-THK5117 in non-alzheimer’s neurodegenerative diseases. Alzheimers Dement 2014; 10: 307–8.
15. 18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2015; 42: 1052–61.
16. 18F-THK5351: A novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med 2016; 57: 208–14.
17. Hasegawa M, Watanabe S, Kondo H, Akiyama H, Mann DM, Saito Y, et al. 3R and 4R tau isoforms in paired helical filaments in Alzheimer’s disease. Acta Neuropathol 2014; 127: 303–5.
18. 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med 2014; 55: 1532–8.
19. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702–5.
20. Ikeda K, Haga C, Kosaka K. Light and electron microscopic examination of amyloid-rich primitive plaques: comparison with diffuse plaques. J Neurol 1990; 237: 88–93.
21. Iwasaki Y, Ito M, Mori K, Deguchi A, Nagaoka M, Yoshida M, et al. An autopsy case of diffuse neurofibrillary tangles with calcification: early stage pathologic findings. Neuropathology 2009; 29: 697–703.
22. Ji B, Chen CJ, Bando K, Ashino H, Shiraishi H, Sano H, et al. Distinct binding of amyloid imaging ligands to unique amyloid-b deposited in the presubiculum of Alzheimer’s disease. J Neurochem 2015; 135: 859–66.
23. Kato S, Nakamura H. Presence of two different fibril subtypes in the Pick body: an immunoelectron microscopic study. Acta Neuropathol 1990; 81: 125–9.
24. 11C-PBB3. J Nucl Med 2015; 56: 1359–65.
25. Ksiezak-Reding H, Morgan K, Mattiace LA, Davies P, Liu WK, Yen SH, et al. Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration. Am J Pathol 1994; 145: 1496–508.
26. Lee VM, Goedert M, Trojanowski JQ Neurodegenerative tauopathies [Review]. Annu Rev Neurosci 2001; 24: 1121–59.
27. Li L, von Bergen M, Mandelkow EM, Mandelkow E. Structure, stability, and aggregation of paired helical filaments from tau protein and FTDP-17 mutants probed by tryptophan scanning mutagenesis. J Biol Chem 2002; 277: 41390–400.
28. Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 2016; 4: 58.
29. Marquié M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015; 78: 787–800.
30. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79: 1094–108.
31. Mitchell TW, Nissanov J, Han LY, Mufson EJ, Schneider JA, Cochran EJ, et al. Novel method to quantify neuropil threads in brains from elders with or without cognitive impairment. J Histochem Cytochem 2000; 48: 1627–38.
32. Murray ME, Kouri N, Lin WL, Jack CR Jr, Dickson DW, Vemuri P. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res Ther 2014; 6: 1.
33. 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 2013; 54: 1420–7.
34. 18F]AV1451 PET in AD and non-AD Tauopahies. Neurology 2015; 84: P5.005.
35. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995; 14: 457–66.
36. 18F]AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and dementias. Alzheimers Dement 2016; 12: 1116–24.
37. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, et al. Distinct tau prion strains propagate in dells and mice and define different tauopathies. Neuron 2014; 82: 1271–88.
38. Schmidt ML, Gur RE, Gur RC, Trojanowski JQ. Intraneuronal and extracellular neurofibrillary tangles exhibit mutually exclusive cytoskeletal antigens. Ann Neurol 1998; 23: 184–9.
39. 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment and Alzheimer’s disease. J Nucl Med 2016; 57: 1535–42.
40. Slowinski J, Dominik J, Uitti RJ, Ahmed Z, Dickson DD, Wszolek ZK. Frontotemporal dementia and Parkinsonism linked to chromosome 17 with the N279K tau mutation. Neuropathology 2007; 27: 73–80.
41. Spector AR, Dugger BN, Wszolek ZK, Uitti RJ, Fredrickson O, Kaplan J, et al. Anatomy of disturbed sleep in pallido-ponto-nigral degeneration. Ann Neurol 2011; 69: 1014–25.
42. Spillantini MG, Crowther RA, Kamphorst W, Heutink P, van Swieten JC. Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau. Am J Pathol 1998; 153: 1359–63.
43. Taniguchi-Watanabe S, Arai T, Kametani F, Nonaka T, Masuda-Suzukake M, Tarutani A, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol 2016; 131: 267–80.
44. Tsuboi Y, Uitti RJ, Delisle MB, Ferreira JJ, Brefel-Courbon C, Rascol O, et al. Clinical features and disease haplotypes of individuals with the N279K tau gene mutation: a comparison of the pallidopontoni-gral degeneration kindred and a French family. Arch Neurol 2002; 59: 943–50.
45. Vermeiren C, Mercier J, Viot D, Mairet-Coello G, Hannestad J, Courade JP, et al. T807, a reported selective Tau tracer, binds with nanomolar affinity to monoamine oxidase A. Alzheimers Dement 2015; 11: P283.
46. 18F]THK-5351 PET in patients with clinically diagnosed progressive supranuclear palsy. J Nucl Med 2016; 57: 457.
47. von Bergen M, Barghorn S, Müller SA, Pickhardt M, Biernat J, Mandelkow EM, et al. The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited pro-teolysis. Biochemistry 2006; 45: 6446–57.
48. 18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement 2013; 9: 666–76.
49. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013; 80: 402–14.